Abstract: The invention provides a composition useful to prepare influenza vaccine viruses, e.g., in the absence of helper virus, which includes internal viral segments from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and encodes a heterologous antigen.

Abstract: Provided herein are, inter alia, methods of identifying agents that are capable of inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.

Abstract: The present invention relates to variants of porcine granulocyte colony stimulating factor (pG-CSF). The pG-CSF variants are useful in treating preventing or reducing the incidence of bacterial infections in swine. Methods of treating swine are disclosed.

Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or animal, and in certain instances reducing the amount of PrP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks spongiform changes in the brain, development of abnormal protein aggregates, neuronal loss, markers of neuronal loss, rapidly progressing dementia, and death. Such neurodegenerative diseases include prion diseases, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), familial Creutzfeldt-Jakob Disease (fCJD), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, kuru, Alzheimer's disease, or Parkinson's disease.

Abstract: Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described.

Abstract: Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includes SEQ?ID?NO:?1 ((I/V)P(P/K/V/E)P(E/K/R/Q)N(A/V)R),? SEQ?ID?NO:?2 ((S/L/V)PAF(A/P)(K/Q)(G/T/E)(N/T/D)),?or? SEQ?ID?NO:?3 (PP(G/T/Q/V)(V/T/A)(R/H/T/S)(GN/NHP/SAA)).

Abstract: A specimen processing system includes a plate for supporting a specimen system, wherein the specimen system includes a container and a specimen contained therein. The specimen processing system further includes a camera disposed above the plate and configured to generate images of the specimen system, a light source disposed beneath the plate for radiating light towards the plate, a light stop for blocking a portion of the light from reaching the specimen system to produce darkfield illumination of the specimen at the camera, and one or more processors electronically coupled to the camera and configured to track a position of the specimen within the specimen container during a specimen processing protocol based on the images.

Abstract: Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to a signal peptide.

Abstract: A device may receive images of a patient, and may perform segmentation of surfaces on the images to create a 3D model. The device may identify normal tissue regions and atrial fibrosis (AF) regions in the 3D model, and may divide the 3D model into the normal tissue regions and the AF regions. The device may assign first cell and tissue properties to the normal tissue regions, and may assign second cell and tissue properties to the AF regions. The device may perform simulations on the normal tissue regions and the AD regions, based on the first and second cell and tissue properties, to generate simulation results, and may extract first features from the simulation results. The device may extract second features from the images, and may process the first and second features, with a model, to select a feature that is predictive of atrial fibrillation recurrence.

Abstract: Induced pluripotent stem cells (iPSCs) derived from a T cell of a T cell subset. T cells derived from iPSCs derived from a T cell. Methods of deriving iPSCs from a T cell. Methods of deriving T cells from iPSCs including deriving a T cell of a T cell subset from an iPSC. Methods of engineering chimeric antigen receptor (CAR)-expressing or T cell receptor (TCR)-expressing iPSC. Methods of administering T cells derived using the methods disclosed. Induced pluripotent stem cell lines derived from T cells, methods of deriving induced pluripotent stem cell lines, and methods of deriving T cells from induced pluripotent stem cell lines.

Abstract: A modified human erythropoietin with an increased plasma half-life, with an erythropoietic activity of less than 0.5% in relation to a native erythropoietin, which maintains the neuroprotective and neuroplastic capacity, which comprises the mutation of at least one of the binding sites the homodimeric or heterodimeric receptor by incorporating consensus sites for N-glycosylation.

Abstract: An automatic analyzer includes a control unit that performs a process when a sample necessary to perform measurement for measurement content selected on an item selection screen is not arranged in a sample-container array unit. The process includes referring to the measurement content selected on the item selection screen and availability information that is information indicating whether each position in the sample-container array unit is available. A position in the sample-container array unit at which a container containing the sample necessary to perform measurement for the selected measurement content is to be arranged is specified in accordance with a specified arrangement rule, and information on the specified position in the sample-container array unit is displayed on a display unit.

Abstract: Chemical compositions and/or mixtures that allow nucleic acid to remain stable at ambient temperatures. The disclosed technology includes a solution and manufacturing methods thereof. The solution includes a chelating agent, a buffering agent, and a salt. The solution is configured to protect RNA and/or an RNA-based vaccine added to the solution and prevents or reduces degradation of the RNA and/or the RNA-based vaccine for a duration of 2 to 180 days over a temperature range of ?20 degrees C. to +38 degrees C. The chelating agent can comprise ethylenediaminetetraacetic acid (EDTA). The buffering agent can comprise tris(hydroxymethyl)aminomethane (TRIS). The salt can comprise NaCl. The solution is configured to preserve an injectable mRNA vaccine added to the solution, and the solution is safe for injection into mammals.

Abstract: The invention provides compositions and methods for reprogramming minimal volumes of mononuclear cells. In particular aspects, the invention provides methods and compositions for reprogramming minimal volumes of umbilical cord blood obtained from cord blood segments from cryopreserved cord blood segments.

Abstract: A method for extracting nucleic acids using suitable solid supports, for example silica-based. In particular, the method includes a step of capturing nucleic acids by placing the sample in contact with a suitable solid support, characterized in that, prior to the capture step, said method includes a step of treating the sample with at least one reagent for masking the amine or carboxylic acid functional groups of the proteins and/or polysaccharides of the sample.

Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Abstract: Provided is an agent for accelerating maturation or aging of cells. An agent for accelerating maturation or aging of cells, comprising KU-60019 as an active ingredient.

Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: Compositions of HLA-G+ MSC and methods of using them, including methods of transplanting compositions of HLA-G+ MSC into human recipients, are provided. Also provided are methods of preparing compositions of HLA-G+ MSC, including by treatment with DNA methylation inhibitors.

Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Abstract: The present invention relates to a gene expression cassette including a synthetic 5? untranslated region (5? UTR), a promoter, and a regulatory gene; a recombinant vector including a replication origin and the gene expression cassette; a recombinant microorganism which has the recombinant vector introduced thereinto and shows alleviated segregational instability and; a method for preparing a recombinant microorganism having alleviated segregational instability by introducing the recombinant vector thereinto; and a method for quantitatively controlling a plasmid copy number in a recombinant microorganism.

Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.

Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.

Abstract: Systems and methods for accurate optical pH sensing of biofilms are disclosed. In one embodiment, a method of measuring an extracellular pH level using multiple wavelengths emitted by a fluorescent substance includes: exciting the fluorescent substance at an excitation wavelength; measuring a first fluorescence intensity at a first wavelength of a fluorescence emission; and measuring a second fluorescence intensity at a second wavelength of the fluorescence emission. The second wavelength is different from the first wavelength. The method also includes determining the extracellular pH level based on the first fluorescence intensity at the first wavelength and the second fluorescence intensity at the second wavelength.

Abstract: This invention relates to dermatology and to treatments of infectious skin disease.

Abstract: Provided is a microfluidic chip for physicochemically treating a single cell whose diameter is 50-400 micrometers.

Abstract: The present invention relates to novel polypeptides, which are derived from Arginase2. The invention also concerns uses of the polypeptides and compositions comprising the polypeptides.

Abstract: The present invention discloses a PET system attenuation correction method based on a flow model. The flow model adopted is a completely reversible model, the forward and reverse mappings share the same parameters, and the structure itself is a consistency constraint. The model utilizes the spatial correlation of adjacent slices, and adopts the structure of multi-slice input and single-slice output. The model consists of multiple reversible blocks, each of which consists of a enhanced affine coupling layer and a reversible 1×1 convolutional layer, and uses several small u-nets to learn the transformation parameters of the enhanced affine coupling layer. The present invention avoids additional CT or MR scanning, saves scanning cost for the patient, and reduces the damage of CT radiation to the patient; compared with similar methods, higher quality non-attenuation-corrected PET image can be obtained.

Abstract: A cell culturing method and device that uses a cell culture bag (1) that includes a bag body (2) configured from an upper surface film (21) and a lower surface film (22) having a sealed periphery, and a port (3) attached to the bag body (2), and a plurality of recesses (4) being formed in the lower surface film (22). The method including: a closing-off step for closing off the plurality of recesses (4) using the upper surface film (21) by discharging a culture medium (S) contained in the bag body (2) through the port (3); and a releasing step for releasing, in some or all of the plurality of closed-off recesses (4), cells or cell aggregates adhering to the inner surfaces of the recesses (4).

Abstract: Methods of reactivating transcription of a fragile X mental retardation 1 (FMR1) gene and treating FMR1-associated diseases are provided. Compositions and kits for doing same are also provided.

Abstract: The present disclosure relates to a cell culture medium that promotes cell proliferation during serum-free cell culture.

Abstract: The present invention relates to a method for isolating and culturing neural stem cells with high efficiency, which may shorten the time for isolation and culture by simplifying a method for isolating and culturing neural stem cells and may increase the acquisition yield of neural stem cells. The present invention provides a method for isolating and culturing neural stem cells with high efficiency, comprising the steps of adding brain tissue into an enzyme solution so as to subject the brain tissue to enzyme treatment; physically isolating cell clumps from the enzyme treated brain tissue by dividing the cell clumps according to size and removing impurities; and inoculating the cell clumps on a culture dish so as to subculture.

Abstract: Provided herein are methods of producing ? cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.

Abstract: This disclosure describes decellularized, biologically-engineered tubular grafts and methods of making and using such decellularized, biologically-engineered tubular grafts.

Abstract: According to the present disclosure, there is provided a method for culturing cells into which a reprogramming factor is introduced including culturing cells into which a reprogramming factor is introduced; and recovering all cells into which the reprogramming factor is introduced and seeding and passaging at least part of the recovered cells in a medium. In addition, there is provided a method for culturing cells into which a reprogramming factor is introduced, including culturing cells into which a reprogramming factor is introduced; and inducing somatic cells different from pluripotent stem cells without passaging the cells into which the reprogramming factor is introduced.

Abstract: The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.

Abstract: A system and method for modulating stress granule assembly, utilizing a protein construct that has a cell penetrating protein fused to one or more proteins that can bind with an NTF2-like domain of a G3BP protein. By configuring the protein construct with an appropriate number of proteins that being with NTF2-like domains, stress granule assembly can be upregulated or downregulated as needed to treat patients.

Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.

Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.

Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.

Abstract: The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

Abstract: The invention provides integrated Organ-on-Chip microphysiological systems representations of living Organs and support structures for such microphysiological systems.

Abstract: Some embodiments provided herein relate to methods and compositions for making genetically modified T cells. In some such embodiments, CD4+ and CD8+ T cells are cultured in a single serum-free volume. In some embodiments, co-cultured CD4+ and CD8+ T cells can be transduced with a lentiviral vector, and a population of transduced T cells can be harvested within a shorter period of time than other conventional methods.

Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGEEHSV (SEQ ID NO: 1) derived from the MAGE-B2 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.

Abstract: The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Abstract: The present invention provides a composition for delivering a polynucleotide into cells via a polyplex. The polyplex comprises the polynucleotide and a polymer. The composition comprises the polyplex, a collagen-mimetic peptide (CMP) and collagen fragments. The CMP is bound to the polyplex and the collagen fragments. Also provided are the uses of the composition in methods of delivering a polynucleotide into cells as well as methods of improving wound healing in a subject, enhancing cell proliferation in a subject, enhancing production of extracellular matrix by cells in a subject and/or enhancing cell migration by cells in a subject.

Abstract: A method and related apparatus for confirming whether a kill laser successfully destroys an undesired population of cells includes introducing fluorescent dye into cells, exciting the cells with a detection laser or a light emitting diode to cause the cell to fluoresce for a first time, measuring the amount of fluorescence in the cells with a detector capable of emitting a detection pulse, classifying the cells via embedded processing as undesired or desired cells based on the amount of fluorescence, firing a kill beam with a kill laser at any undesired cells, measuring the amount of fluorescence in the cells a second time to determine whether a fluorescent event was generated from the kill beam striking the cells, and providing feedback to an operator of the kill laser as to whether any fluorescent events were generated from the kill beam striking the cells.

Abstract: The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.